Prescription attached:-

đŠē COMPLETE PRESCRIPTION ANALYSIS & FINAL CLINICAL WORKING ASSESSMENT
āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύā§āϰ āĻĒā§āϰā§āĻŖāĻžāĻā§āĻ āĻŦāĻŋāĻļā§āϞā§āώāĻŖ, āϏāĻ āĻŋāĻ āĻāώā§āϧ āĻļāύāĻžāĻā§āϤāĻāϰāĻŖ, āϰā§āĻāύāĻŋāϰā§āĻŖā§ āĻāĻŦāĻ āĻāĻŋāĻāĻŋā§āϏāĻž āĻĒāϰāĻŋāĻāϞā§āĻĒāύāĻž
Author: Md. Rafiqul Islam Lipu
Date: Tuesday, 13 October 2026
Time: 8:47 PM (Bangladesh Standard Time)
Clinical References: Bailey & Love, Harrison’s Internal Medicine, CDC, WSES, AAFP āĻāĻŦāĻ MedEx BangladeshāĨ¤
Prescription Source: āĻāĻĒāĻā§āϞāĻž āϏā§āĻŦāĻžāϏā§āĻĨā§āϝ āĻāĻŽāĻĒā§āϞā§āĻā§āϏ, āĻŽāĻĻāύ, āύā§āϤā§āϰāĻā§āύāĻžāĨ¤
āϏāĻāĻļā§āϧāĻŋāϤ āĻā§āϰā§āϤā§āĻŦāĻĒā§āϰā§āĻŖ āϤāĻĨā§āϝ
āĻāĻĒāύāĻžāϰ āĻĻā§āĻā§āĻž āϏāĻāĻļā§āϧāύ āĻ āύā§āϏāĻžāϰ⧠āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύāĻāĻŋ āύāϤā§āύ āĻāϰ⧠āĻŦāĻŋāĻļā§āϞā§āώāĻŖ āĻāϰāĻž āĻšā§ā§āĻā§āĨ¤
āĻŦāĻŋāĻļā§āώ āĻāϰā§:
- Tab. Solivo 500 mg: āĻāĻāĻŋ āĻļā§āϧ⧠Naproxen 500 mg āύā§; MedEx āĻ āύā§āϝāĻžā§ā§ āĻāϰ āϏāĻŽā§āĻĒā§āϰā§āĻŖ composition āĻšāϞ⧠Naproxen Sodium 500 mg + Esomeprazole Magnesium 20 mgāĨ¤
- Viodin Wash: āĻāĻŋāĻāĻŋā§āϏāĻ Debridement āĻ wound care-āĻāϰ āĻāύā§āϝ Viodin wash āĻāϞā§āϞā§āĻ āĻāϰā§āĻā§āύāĨ¤ āĻāĻāĻŋ Povidone Iodine-āĻāϰ āĻāĻāĻāĻŋ brand; Betadine āύā§āĨ¤
- Inj. Vaxitet + IG: āĻāĻāĻžāύ⧠āĻāĻŋāĻā§āύāĻžāϏ āĻĒā§āϰāϤāĻŋāϰā§āϧ⧠vaccine āĻāĻŦāĻ āϏāĻŽā§āĻāĻžāĻŦā§āϝ immunoglobulin/antitoxin āĻŦā§āϝāĻŦāĻšāĻžāϰā§āϰ āύāĻŋāϰā§āĻĻā§āĻļ āϰā§ā§āĻā§āĨ¤
Clinical limitation: āĻāĻāĻŋ āϏāĻŽā§āĻāĻŦāϤ ā§§ā§§ āĻ āĻā§āĻā§āĻŦāϰ ⧍ā§Ļā§¨ā§Š āϏāĻžāϞā§āϰ āĻāĻāĻāĻŋ āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύāĨ¤ āϰā§āĻā§āϰ āĻŦāϰā§āϤāĻŽāĻžāύ āĻ āĻŦāϏā§āĻĨāĻž, āĻā§āώāϤā§āϰ āϏā§āĻĨāĻžāύ, āĻļāĻžāϰā§āϰāĻŋāĻ āĻĒāϰā§āĻā§āώāĻžāϰ āĻĢāϞāĻžāĻĢāϞ āĻāĻŦāĻ āĻāĻŋāĻāĻŋā§āϏāĻž āϏāĻŽā§āĻĒāύā§āύ āĻšā§ā§āĻā§ āĻāĻŋ āύāĻž āĻāĻžāύāĻž āύā§āĻāĨ¤ āϤāĻžāĻ āύāĻŋāĻā§āϰ āϰā§āĻāύāĻŋāϰā§āĻŖā§āĻāĻŋ āĻĒā§āϰā§āύ⧠āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύāĻāĻŋāϤā§āϤāĻŋāĻ clinical working assessment, āύāϤā§āύ āĻļāĻžāϰā§āϰāĻŋāĻ āĻĒāϰā§āĻā§āώāĻžāϰ āĻŦāĻŋāĻāϞā§āĻĒ āύā§āĨ¤
1. Patient Information â āϰā§āĻā§āϰ āϤāĻĨā§āϝ
| Parameter | Findings |
|---|---|
| Healthcare Facility | Upazila Health Complex, Madan, Netrokona |
| Department | Emergency Department |
| Patient’s Age | āĻāύā§āĻŽāĻžāύāĻŋāĻ ā§Šā§Ē āĻŦāĻāϰ |
| Prescription Date | āϏāĻŽā§āĻāĻŦāϤ 11 October 2023 |
| Presenting Problem | Accidental Impaction of Rusty Materials |
| Doctor’s Diagnosis | Foreign Body (FB) Impaction |
| Treatment Approach | Foreign Body Removal, Wound Management āĻāĻŦāĻ Tetanus Prophylaxis |
Clinical Interpretation:
āϰā§āĻā§āϰ āĻļāϰā§āϰā§āϰ āĻā§āύ⧠āĻāĻāĻāĻŋ āĻ āĻāĻļā§ āĻĻā§āϰā§āĻāĻāύāĻžāĻŦāĻļāϤ āĻŽāϰāĻŋāĻāĻžāϝā§āĻā§āϤ āĻŦāϏā§āϤ⧠āĻĒā§āϰāĻŦā§āĻļ āĻāϰā§āĻā§ āĻŦāϞ⧠āĻāĻŋāĻāĻŋā§āϏāĻ āĻāϞā§āϞā§āĻ āĻāϰā§āĻā§āύāĨ¤
āĻāĻ āĻĒāϰāĻŋāϏā§āĻĨāĻŋāϤāĻŋāϤ⧠āϏāĻŽā§āĻāĻžāĻŦā§āϝ āϏāĻŽāϏā§āϝāĻž āĻšāϞ⧠Penetrating Soft-Tissue Injury with Foreign Body ImpactionāĨ¤
2. C/C â Chief Complaints
āϰā§āĻā§āϰ āĻĒā§āϰāϧāĻžāύ āĻ āĻāĻŋāϝā§āĻ
āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύ⧠āĻāϞā§āϞā§āĻ āĻāϰāĻž āĻšā§ā§āĻā§:
H/O Accidental Impaction of Rusty Materials
āĻŦāĻžāĻāϞāĻž āĻ āϰā§āĻĨ: āĻĻā§āϰā§āĻāĻāύāĻžāĻŦāĻļāϤ āĻŽāϰāĻŋāĻāĻžāϝā§āĻā§āϤ āĻā§āύ⧠āĻŦāϏā§āϤ⧠āĻļāϰā§āϰā§āϰ āĻāĻŋāϏā§āϝā§āϤ⧠āĻĒā§āϰāĻŦā§āĻļ āĻāϰāĻžāϰ āĻāϤāĻŋāĻšāĻžāϏāĨ¤
āĻāĻāĻžāύā§:
H/O = History Of â āϰā§āĻā§āϰ āĻāĻāύāĻžāϰ āĻāϤāĻŋāĻšāĻžāϏāĨ¤
Accidental = āĻĻā§āϰā§āĻāĻāύāĻžāĻāύāĻŋāϤāĨ¤
Impaction = āĻā§āύ⧠āĻŦāϏā§āϤ⧠āĻāĻāĻā§ āϝāĻžāĻā§āĻžāĨ¤
Rusty Materials = āĻŽāϰāĻŋāĻāĻžāϝā§āĻā§āϤ āĻŦāϏā§āϤā§āĨ¤
Clinical Interpretation
āĻāĻ āĻāϤāĻŋāĻšāĻžāϏ Penetrating Injury āĻ Foreign Body Impaction-āĻāϰ āϏāĻā§āĻā§ āϏāĻžāĻŽāĻā§āĻāϏā§āϝāĻĒā§āϰā§āĻŖāĨ¤
āϤāĻŦā§ āĻŦā§āϝāĻĨāĻž, āϰāĻā§āϤāĻĒāĻžāϤ, āĻĢā§āϞāĻž, āĻā§āĻŦāϰ āĻ āĻĨāĻŦāĻž āĻĒā§āĻāĻ āĻšāĻā§āĻžāϰ āĻāĻĨāĻž āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύ⧠āϏā§āĻĒāώā§āĻāĻāĻžāĻŦā§ āϞā§āĻāĻž āύā§āĻāĨ¤
Confidence: 0.95
3. Patient History â āĻāĻŋāĻāĻŋā§āϏāĻā§āϰ āĻāϞā§āϞā§āĻ āĻāϰāĻž āĻāϤāĻŋāĻšāĻžāϏ
| History | Prescription Findings |
|---|---|
| History of Trauma | Present |
| Accidental Injury | Present |
| Rusty Material Exposure | Present |
| Foreign Body Impaction | Mentioned |
| Previous Tetanus Vaccination | Not mentioned |
| Diabetes Mellitus | Not mentioned |
| Hypertension | Not mentioned |
| Drug Allergy | Not mentioned |
| Previous Surgery | Not mentioned |
| Duration Since Injury | Not mentioned |
My Clinical Observation
āĻāĻ āϰā§āĻā§āϰ āĻā§āώā§āϤā§āϰ⧠āĻā§ā§āĻāĻāĻŋ āĻā§āϰā§āϤā§āĻŦāĻĒā§āϰā§āĻŖ History āĻ āύā§āĻĒāϏā§āĻĨāĻŋāϤ āϰā§ā§āĻā§āĨ¤
āĻŦāĻŋāĻļā§āώāϤ:
- Site of Injury: āĻļāϰā§āϰā§āϰ āĻā§āύ āĻāĻžā§āĻāĻžā§ āĻāĻāĻžāϤ āϞā§āĻā§āĻā§?
- Time Since Injury: āĻāϤāĻā§āώāĻŖ āĻāĻā§ āĻāĻāĻžāϤ āϞā§āĻā§āĻā§?
- Nature of Foreign Body: āĻĒā§āϰā§āĻ, āϞā§āĻšāĻž, āϤāĻžāϰ āύāĻžāĻāĻŋ āĻ āύā§āϝ āĻŦāϏā§āϤā§?
- Tetanus Vaccination History: āĻļā§āώ āĻāĻŋāĻāĻž āĻāĻāύ āĻĻā§āĻā§āĻž āĻšā§ā§āĻāĻŋāϞ?
- Past Medical History: āĻĄāĻžā§āĻžāĻŦā§āĻāĻŋāϏ āĻ āĻĨāĻŦāĻž āϰā§āĻāĻĒā§āϰāϤāĻŋāϰā§āϧāĻā§āώāĻŽāϤāĻž āĻāĻŽ āĻĨāĻžāĻāĻžāϰ āĻāϤāĻŋāĻšāĻžāϏ āϰā§ā§āĻā§ āĻāĻŋ?
āĻāĻā§āϞ⧠āĻāĻŋāĻāĻŋā§āϏāĻžāϰ āϏāĻŋāĻĻā§āϧāĻžāύā§āϤāĻā§ āĻĒā§āϰāĻāĻžāĻŦāĻŋāϤ āĻāϰā§āĨ¤
4. O/E â On Examination
āĻļāĻžāϰā§āϰāĻŋāĻ āĻĒāϰā§āĻā§āώāĻžā§ āĻā§ āĻĒāĻžāĻā§āĻž āĻā§āĻā§?
āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύ⧠āĻāϞāĻžāĻĻāĻž āĻāϰ⧠O/E findings āϞā§āĻāĻž āύā§āĻāĨ¤
| Examination | Status |
|---|---|
| Pulse | Not documented |
| Blood Pressure | Not documented |
| Temperature | Not documented |
| Wound Location | Not clearly documented |
| Wound Depth | Not documented |
| Local Tenderness | Not documented |
| Swelling | Not documented |
| Pus Discharge | Not documented |
| Neurovascular Examination | Not documented |
Recommended Clinical Examination
āĻā§āώāϤ āĻĒāϰā§āĻā§āώāĻž āĻāϰ⧠āĻĻā§āĻāϤ⧠āĻšāĻŦā§:
- Foreign Body āĻĻā§āĻļā§āϝāĻŽāĻžāύ āĻŦāĻž āϏā§āĻĒāϰā§āĻļā§ āĻŦā§āĻāĻž āϝāĻžāĻā§āĻā§ āĻāĻŋ āύāĻžāĨ¤
- āϏā§āĻĨāĻžāύā§ā§ tenderness, swelling āĻāĻŦāĻ erythema āĻāĻā§ āĻāĻŋ āύāĻžāĨ¤
- āĻā§āώāϤ āĻĨā§āĻā§ discharge āĻŦā§āϰ āĻšāĻā§āĻā§ āĻāĻŋ āύāĻžāĨ¤
- āĻāĻļāĻĒāĻžāĻļā§āϰ nerve, tendon āĻ blood vessel āĻā§āώāϤāĻŋāĻā§āϰāϏā§āϤ āĻšā§ā§āĻā§ āĻāĻŋ āύāĻžāĨ¤
Clinical Note: āĻāĻŋāĻāĻŋā§āϏāĻ Drainage āϞāĻŋāĻā§āĻā§āύ āĻŦāϞ⧠āϰā§āĻā§āϰ abscess āĻāĻŋāϞâāĻāĻŽāύ āϏāĻŋāĻĻā§āϧāĻžāύā§āϤ āύā§āĻā§āĻž āϝāĻžāĻŦā§ āύāĻžāĨ¤
5. Doctor's Diagnosis â āĻāĻŋāĻāĻŋā§āϏāĻā§āϰ āϰā§āĻāύāĻŋāϰā§āĻŖā§
āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύ⧠āϞā§āĻāĻž āϰā§ā§āĻā§:
FB Impaction
Full Form: Foreign Body Impaction.
āĻŦāĻžāĻāϞāĻž āĻ āϰā§āĻĨ
āĻļāϰā§āϰā§āϰ āĻāĻŋāϏā§āϝā§āϰ āĻŽāϧā§āϝ⧠āĻŦāĻžāĻāϰā§āϰ āĻā§āύ⧠āĻŦāϏā§āϤ⧠āĻĒā§āϰāĻŦā§āĻļ āĻāϰ⧠āĻāĻāĻā§ āϝāĻžāĻā§āĻžāĨ¤
Pathophysiology â āϰā§āĻā§āϰ āĻĒā§āϰāĻā§āϰāĻŋā§āĻž
āϝāĻāύ āĻā§āύ⧠āϧāĻžāϰāĻžāϞ⧠āĻŦāϏā§āϤ⧠āϤā§āĻŦāĻ āĻā§āĻĻ āĻāϰ⧠āĻāĻŋāϏā§āϝā§āϰ āĻŽāϧā§āϝ⧠āĻĒā§āϰāĻŦā§āĻļ āĻāϰā§, āϤāĻāύ āϏā§āĻĨāĻžāύā§ā§āĻāĻžāĻŦā§ tissue disruption, bleeding āĻāĻŦāĻ inflammatory response āϏā§āώā§āĻāĻŋ āĻšāϤ⧠āĻĒāĻžāϰā§āĨ¤
Foreign Body āĻāĻŋāϏā§āϝā§āϰ āĻŽāϧā§āϝ⧠āĻāĻāĻā§ āĻĨāĻžāĻāϞā§:
- Persistent inflammation āĻšāϤ⧠āĻĒāĻžāϰā§āĨ¤
- Local pain āĻšāϤ⧠āĻĒāĻžāϰā§āĨ¤
- Bacterial infection-āĻāϰ āĻā§āĻāĻāĻŋ āĻŦāĻžā§āϤ⧠āĻĒāĻžāϰā§āĨ¤
- Abscess āϤā§āϰāĻŋ āĻšāϤ⧠āĻĒāĻžāϰā§āĨ¤
- āĻāĻā§āϰ āĻāĻāĻžāϤ⧠nerve āĻŦāĻž tendon injury āĻšāϤ⧠āĻĒāĻžāϰā§āĨ¤
āϤāĻŦā§ āĻāĻā§āϞ⧠āϏāĻŽā§āĻāĻžāĻŦā§āϝ āĻāĻāĻŋāϞāϤāĻž; āĻāĻ āϰā§āĻā§āϰ āĻā§āώā§āϤā§āϰ⧠āϏāĻŦāĻā§āϞ⧠āĻāĻĒāϏā§āĻĨāĻŋāϤ āĻāĻŋāϞ āĻŦāϞ⧠āĻĒā§āϰāĻŽāĻžāĻŖ āύā§āĻāĨ¤
6. Doctor's Advice â āĻāĻŋāĻāĻŋā§āϏāĻā§āϰ āĻĒāϰāĻžāĻŽāϰā§āĻļ
āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύā§āϰ Advice āĻ āĻāĻļā§ āϞā§āĻāĻž āϰā§ā§āĻā§:
1. Excision
āĻŦāĻžāĻāϞāĻž: āĻĒā§āϰā§ā§āĻāύā§ā§ āĻāĻŋāϏā§āϝ⧠āĻā§āĻā§ āĻ āĻĒāϏāĻžāϰāĻŖ āĻāϰāĻžāϰ āĻĒā§āϰāĻā§āϰāĻŋā§āĻžāĨ¤
āĻā§āώāϤā§āϰ āĻ āĻŦāϏā§āĻĨāĻžāύ āĻ āύā§āϝāĻžā§ā§ foreign body āĻ āĻĒāϏāĻžāϰāĻŖ āĻŦāĻž āĻā§āώāϤāĻŋāĻā§āϰāϏā§āϤ āĻāĻŋāϏā§āϝ⧠āĻĒāϰāĻŋāώā§āĻāĻžāϰā§āϰ āĻāύā§āϝ surgical excision āĻĒā§āϰā§ā§āĻāύ āĻšāϤ⧠āĻĒāĻžāϰā§āĨ¤
2. Drainage
āĻŦāĻžāĻāϞāĻž: āĻā§āώāϤ⧠āĻāĻŽā§ āĻĨāĻžāĻāĻž āϤāϰāϞ āĻŦāĻž āĻĒā§āĻāĻ āĻŦā§āϰ āĻāϰ⧠āĻĻā§āĻā§āĻžāĨ¤
āϝāĻĻāĻŋ āϏā§āĻĨāĻžāύā§ā§ abscess āĻĨāĻžāĻā§, āϤāĻžāĻšāϞ⧠incision and drainage āĻĒā§āϰā§ā§āĻāύ āĻšāϤ⧠āĻĒāĻžāϰā§āĨ¤
āϤāĻŦā§ āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύ⧠abscess āύāĻŋāĻļā§āĻāĻŋāϤ āĻāϰāĻž āĻšā§āύāĻŋāĨ¤
3. Expulsion of FB
āĻŦāĻžāĻāϞāĻž: āĻļāϰā§āϰā§āϰ āĻŽāϧā§āϝ⧠āĻāĻāĻā§ āĻĨāĻžāĻāĻž āĻŦāĻžāĻāϰā§āϰ āĻŦāϏā§āϤ⧠āĻŦā§āϰ āĻāϰāĻžāĨ¤
āĻāĻāĻŋ āĻāĻŋāĻāĻŋā§āϏāĻā§āϰ āĻ āύā§āϝāϤāĻŽ āĻĒā§āϰāϧāĻžāύ āĻāĻŋāĻāĻŋā§āϏāĻž-āĻāĻĻā§āĻĻā§āĻļā§āϝāĨ¤
4. Debridement
āĻŦāĻžāĻāϞāĻž: āĻā§āώāϤ āĻĨā§āĻā§ āĻŽā§āϤ, āĻā§āώāϤāĻŋāĻā§āϰāϏā§āϤ āĻ āĻĨāĻŦāĻž āĻĻā§āώāĻŋāϤ āĻāĻŋāϏā§āϝ⧠āĻ āĻĒāϏāĻžāϰāĻŖ āĻāϰāĻžāĨ¤
5. Viodin Wash
āĻŦāĻžāĻāϞāĻž: āĻā§āώāϤāϏā§āĻĨāĻžāύā§āϰ antiseptic cleaning-āĻāϰ āĻāύā§āϝ Viodin āĻŦā§āϝāĻŦāĻšāĻžāϰāĨ¤
āĻā§āϰā§āϤā§āĻŦāĻĒā§āϰā§āĻŖ āĻĒāĻžāϰā§āĻĨāĻā§āϝ: Debridement āĻāĻŦāĻ Viodin wash āĻāĻ āĻŦāĻŋāώ⧠āύā§āĨ¤ Debridement āĻšāϞ⧠devitalized tissue āĻ āĻĒāϏāĻžāϰāĻŖ; Viodin āĻšāϞ⧠antiseptic preparationāĨ¤
Deep wound-āĻāϰ irrigation-āĻāϰ āĻāύā§āϝ normal saline āϏāĻžāϧāĻžāϰāĻŖāϤ āĻāĻĒāϝā§āĻā§āϤāĨ¤ āύāĻŋā§āĻŽāĻŋāϤ concentrated povidone-iodine āĻĻāĻŋā§ā§ āĻāĻā§āϰ āĻā§āώāϤā§āϰ āĻā§āϤāϰ irrigation āĻāϰāϞ⧠tissue irritation āĻ healing impairment āĻšāϤ⧠āĻĒāĻžāϰā§āĨ¤
Advice Summary
Excision, Drainage, Foreign Body Removal, Debridement and Viodin Wash.
āĻāĻ āύāĻŋāϰā§āĻĻā§āĻļāύāĻžāĻā§āϞ⧠āϞā§āĻāĻž āĻšā§ā§āĻā§āĨ¤ āĻŦāĻžāϏā§āϤāĻŦā§ āĻĒā§āϰāϤāĻŋāĻāĻŋ procedure āϏāĻŽā§āĻĒāύā§āύ āĻšā§ā§āĻāĻŋāϞ āĻāĻŋ āύāĻž, āϤāĻž āύāĻŋāĻļā§āĻāĻŋāϤ āύā§āĨ¤
7. Prescribed Drug Analysis â MedEx āĻ āύā§āϝāĻžā§ā§
āĻāĻ āĻ āĻāĻļā§ āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύā§āϰ āĻāώā§āϧāĻā§āϞ⧠Brand Name, Generic Name, MedEx Therapeutic Class, Pharmacological Class, Composition, Price, Indications āĻāĻŦāĻ Patient-specific Purpose āĻ āύā§āϝāĻžā§ā§ āĻŦāĻŋāĻļā§āϞā§āώāĻŖ āĻāϰāĻž āĻšāϞā§āĨ¤
Drug No. 1 â Inj. Vaxitet
Brand Name: Vaxitet
Generic Name: Adsorbed Tetanus Vaccine
Composition: 40 IU/0.5 ml
Manufacturer: Incepta Pharmaceuticals Ltd.
Dosage Form: Intramuscular Injection
MedEx Therapeutic Class
Vaccines, Anti-sera & Immunoglobulin
Pharmacological Class
Tetanus Toxoid Vaccine â Active Immunizing Agent
Price According to MedEx
| Presentation | Price |
|---|---|
| 0.5 ml Ampoule | ā§ŗ60.00 |
| 0.5 ml Vial | ā§ŗ95.00 |
| Pack of 10 Ampoules | ā§ŗ600.00 |
MedEx Link: Vaxitet 40 IU/0.5 ml â MedEx
Use of Purpose the Drug
Vaxitet āĻšāϞ⧠Tetanus āĻĒā§āϰāϤāĻŋāϰā§āϧā§āϰ āĻāĻŋāĻāĻžāĨ¤
āĻāĻ vaccine āĻļāϰā§āϰāĻā§ Clostridium tetani-āĻāϰ toxin-āĻāϰ āĻŦāĻŋāϰā§āĻĻā§āϧ⧠protective antibody āϤā§āϰāĻŋ āĻāϰāϤ⧠āĻāĻĻā§āĻĻā§āĻĒāĻŋāϤ āĻāϰā§āĨ¤
āĻā§āύ āĻā§āύ āĻā§āώā§āϤā§āϰ⧠āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻšā§?
- Tetanus prevention following injury.
- Routine tetanus immunization.
- Tetanus booster vaccination.
- Appropriate immunization schedules during pregnancy.
Why Doctor Prescribed This Drug in This Patient
āϰā§āĻā§āϰ āĻĻā§āϰā§āĻāĻāύāĻžāĻāύāĻŋāϤ penetrating injury āĻšā§ā§āĻāĻŋāϞ āĻāĻŦāĻ rusty material-āĻāϰ āĻāϤāĻŋāĻšāĻžāϏ āϰā§ā§āĻā§āĨ¤
Puncture āĻŦāĻž penetrating wound āĻāĻŋāĻā§āύāĻžāϏā§āϰ āĻāύā§āϝ high-risk wound category-āϤ⧠āĻĒā§āϤ⧠āĻĒāĻžāϰā§āĨ¤
āϤāĻžāĻ āĻāĻŋāĻāĻŋā§āϏāĻ āϏāĻŽā§āĻāĻŦāϤ Post-exposure Tetanus Prophylaxis-āĻāϰ āĻāĻĻā§āĻĻā§āĻļā§āϝ⧠Vaxitet āϞāĻŋāĻā§āĻā§āύāĨ¤
Confidence: 0.98
Clinical Note
āĻŽāϰāĻŋāĻāĻž āύāĻŋāĻā§ āĻāĻŋāĻā§āύāĻžāϏ āϏā§āώā§āĻāĻŋ āĻāϰ⧠āύāĻžāĨ¤
āĻāĻŋāĻā§āύāĻžāϏ āĻšā§ Clostridium tetani āύāĻžāĻŽāĻ āĻŦā§āϝāĻžāĻāĻā§āϰāĻŋā§āĻžāϰ toxin-āĻāϰ āĻāĻžāϰāĻŖā§āĨ¤
āĻāĻŋāĻāĻž āĻĒā§āϰā§ā§āĻāύ āĻāĻŋ āύāĻž, āϤāĻž āĻā§āώāϤā§āϰ āϧāϰāύ āĻ āĻĒā§āϰā§āĻŦāĻŦāϰā§āϤ⧠vaccination history āĻ āύā§āϝāĻžā§ā§ āύāĻŋāϰā§āϧāĻžāϰāĻŖ āĻāϰāϤ⧠āĻšā§āĨ¤
CDC 2026 āĻ āύā§āϝāĻžā§ā§ dirty wound-āĻāϰ āĻā§āώā§āϤā§āϰ⧠primary vaccine series āϏāĻŽā§āĻĒā§āϰā§āĻŖ āĻĨāĻžāĻāϞā§āĻ āĻļā§āώ tetanus vaccine āĻĒāĻžāĻāĻ āĻŦāĻāϰ āĻŦāĻž āϤāĻžāϰ āĻŦā§āĻļāĻŋ āĻāĻā§ āĻĻā§āĻā§āĻž āĻšāϞ⧠booster āĻĒā§āϰā§ā§āĻāύ āĻšāϤ⧠āĻĒāĻžāϰā§āĨ¤
Drug No. 2 â Tetanus IG
āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύ⧠Vaxitet + IG āϞā§āĻāĻž āϰā§ā§āĻā§āĨ¤
āĻāĻāĻžāύ⧠IG-āĻāϰ āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ preparation āύāĻŋāĻļā§āĻāĻŋāϤāĻāĻžāĻŦā§ āĻļāύāĻžāĻā§āϤ āĻāϰāĻž āϝāĻžā§āύāĻŋāĨ¤
āϤāĻžāĻ Human Tetanus Immunoglobulin āĻāĻŦāĻ Equine Tetanus Antitoxin āĻāϞāĻžāĻĻāĻž āĻāϰ⧠āĻŦā§āĻāϤ⧠āĻšāĻŦā§āĨ¤
A. Human Tetanus Immunoglobulin
Generic Name: Human Tetanus Immunoglobulin
MedEx Therapeutic Class
Vaccines, Anti-sera & Immunoglobulin
Pharmacological Class
Passive Immunizing Agent
Bangladesh Available Brands
| Brand | Company | Composition | Price |
|---|---|---|---|
| Protet-IG | Incepta | 250 IU/ml | ā§ŗ975 |
| Tetagam-P | CSL Behring | 250 IU/ml | ā§ŗ1,300 |
MedEx Link: Protet-IG â MedEx
Use of Purpose the Drug
Human TIG āϏāϰāĻžāϏāϰāĻŋ antibody āϏāϰāĻŦāϰāĻžāĻš āĻāϰ⧠āϏāĻžāĻŽā§āĻŋāĻ passive protection āĻĻā§ā§āĨ¤
Why Would the Doctor Prescribe This Drug?
āϰā§āĻā§āϰ tetanus vaccination history āĻ āĻāĻžāύāĻž āĻ āĻĨāĻŦāĻž āĻ āϏāĻŽā§āĻĒā§āϰā§āĻŖ āĻĨāĻžāĻāϞ⧠TIG āĻĒā§āϰā§ā§āĻāύ āĻšāϤ⧠āĻĒāĻžāϰā§āĨ¤
CDC Guideline â 2026
Dirty āĻŦāĻž penetrating wound-āĻāϰ āĻā§āώā§āϤā§āϰ⧠TIG āĻŦāĻŋāĻŦā§āĻā§āϝ, āϝāĻĻāĻŋ āϰā§āĻā§āϰ:
- Vaccination history unknown āĻĨāĻžāĻā§āĨ¤
- Primary vaccination series incomplete āĻĨāĻžāĻā§āĨ¤
- Previously unvaccinated āĻšāĻā§āĻžāϰ āĻāϤāĻŋāĻšāĻžāϏ āĻĨāĻžāĻā§āĨ¤
- HIV āĻ āĻĨāĻŦāĻž severe immunodeficiency āĻĨāĻžāĻā§āĨ¤
Recommended Human TIG prophylactic dose, when indicated: 250 IU IM.
B. Vaxitet-IG â Equine Tetanus Antitoxin
āĻŦāĻžāĻāϞāĻžāĻĻā§āĻļā§ Vaxitet-IG āύāĻžāĻŽā§āϰ āĻāϰā§āĻāĻāĻŋ preparation āĻĒāĻžāĻā§āĻž āϝāĻžā§āĨ¤
| Parameter | Information |
|---|---|
| Brand | Vaxitet-IG |
| Generic | Tetanus Antitoxin (Equine) |
| Composition | 3000 IU/ml |
| Manufacturer | Incepta |
| Unit Price | ā§ŗ408 per vial |
MedEx Link: Vaxitet-IG â MedEx
Important Difference
Human TIG āĻāĻŦāĻ Equine Tetanus Antitoxin āĻāĻāĻ āĻāώā§āϧ āύā§āĨ¤
Equine antitoxin-āĻ hypersensitivity, anaphylaxis āĻ serum sickness-āĻāϰ āĻā§āĻāĻāĻŋ āĻŦā§āĻļāĻŋāĨ¤
Human TIG āĻĒāĻžāĻā§āĻž āĻā§āϞ⧠āϏā§āĻāĻŋāĻ āϏāĻžāϧāĻžāϰāĻŖāϤ āĻĒāĻāύā§āĻĻāύā§ā§ passive immunizing preparationāĨ¤
āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύā§āϰ IG āĻ āĻāĻļāĻāĻŋ āĻĻā§āĻā§ āĻā§āύ preparation āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻāϰāĻž āĻšā§ā§āĻāĻŋāϞ, āϤāĻž āύāĻŋāĻļā§āĻāĻŋāϤ āĻŦāϞāĻž āϝāĻžāĻā§āĻā§ āύāĻžāĨ¤
Identification Confidence: 0.50
Drug No. 3 â Cap. Polycef 500 mg
Brand Name
Polycef 500 mg
Generic Name
Cephradine 500 mg
Manufacturer
Renata PLC
MedEx Therapeutic Class
First Generation Cephalosporins
Pharmacological Class
First-generation Cephalosporin Antibiotic
Unit Price and Strip Price
| Presentation | Price |
|---|---|
| Unit Price | ā§ŗ12.54 |
| Strip Price (4 capsules) | ā§ŗ50.16 |
| Pack Price (28 capsules) | ā§ŗ351.12 |
Other Available Compositions
| Composition | Dosage Form |
|---|---|
| 250 mg | Capsule |
| 500 mg | Capsule |
| 125 mg/5 ml | Suspension |
| 250 mg/5 ml | Suspension |
| 125 mg/1.25 ml | Pediatric Drops |
| 500 mg/vial | Injection |
| 1 g/vial | Injection |
MedEx Link: Polycef 500 mg â MedEx
Mechanism of Action
Cephradine āĻāĻāĻāĻŋ beta-lactam antibioticāĨ¤
āĻāĻāĻŋ āĻŦā§āϝāĻžāĻāĻā§āϰāĻŋā§āĻžāϰ cell-wall synthesis āĻŦāĻžāϧāĻžāĻā§āϰāϏā§āϤ āĻāϰā§āĨ¤
āĻĢāϞ⧠āϏāĻāĻŦā§āĻĻāύāĻļā§āϞ āĻŦā§āϝāĻžāĻāĻā§āϰāĻŋā§āĻž āϧā§āĻŦāĻāϏ āĻšā§āĨ¤
Use of Purpose the Drug
Polycef āĻŽā§āϞāϤ susceptible bacterial infection-āĻāϰ āĻāĻŋāĻāĻŋā§āϏāĻžā§ āĻŦā§āϝāĻŦāĻšā§āϤ āĻšā§āĨ¤
āĻā§āύ āĻā§āύ āϰā§āĻā§ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻšā§?
- Skin and Soft Tissue Infection: āϤā§āĻŦāĻ āĻ āύāϰāĻŽ āĻāĻŋāϏā§āϝā§āϰ āϏāĻāĻā§āϰāĻŽāĻŖāĨ¤
- Cellulitis: āϤā§āĻŦāĻ āĻ subcutaneous tissue-āĻāϰ āϏāĻāĻā§āϰāĻŽāĻŖāĨ¤
- Abscess: āĻāĻĒāϝā§āĻā§āϤ āĻā§āώā§āϤā§āϰ⧠āĻĒā§āĻāĻāϝā§āĻā§āϤ āϏāĻāĻā§āϰāĻŽāĻŖ; drainage āĻĒā§āϰā§ā§āĻāύ āĻšāϤ⧠āĻĒāĻžāϰā§āĨ¤
- Respiratory Tract Infection: āϏāĻāĻŦā§āĻĻāύāĻļā§āϞ āĻŦā§āϝāĻžāĻāĻā§āϰāĻŋā§āĻžāĻāύāĻŋāϤ āĻļā§āĻŦāĻžāϏāϤāύā§āϤā§āϰā§āϰ āϏāĻāĻā§āϰāĻŽāĻŖāĨ¤
- Urinary Tract Infection: āϏāĻāĻŦā§āĻĻāύāĻļā§āϞ āĻŦā§āϝāĻžāĻāĻā§āϰāĻŋā§āĻžāϰ āĻāĻžāϰāĻŖā§ āĻŽā§āϤā§āϰāύāĻžāϞāĻŋāϰ āϏāĻāĻā§āϰāĻŽāĻŖāĨ¤
Why Doctor Prescribed Polycef in This Patient
āĻāĻŋāĻāĻŋā§āϏāĻ āϏāĻŽā§āĻāĻŦāϤ contaminated wound-āĻāϰ bacterial infection āĻĒā§āϰāϤāĻŋāϰā§āϧ āĻ āĻĨāĻŦāĻž āϏāĻŽā§āĻāĻžāĻŦā§āϝ āϏā§āĻĨāĻžāύā§ā§ āϏāĻāĻā§āϰāĻŽāĻŖā§āϰ āĻāĻŋāĻāĻŋā§āϏāĻžāϰ āĻāύā§āϝ Polycef āĻĻāĻŋā§ā§āĻā§āύāĨ¤
āϤāĻŦā§ āĻā§āύ⧠āĻā§āώāϤ⧠antibiotic āĻĒā§āϰā§ā§āĻāύ āĻāĻŋ āύāĻž, āϤāĻž āύāĻŋāϰā§āĻāϰ āĻāϰā§:
- āĻā§āώāϤā§āϰ āĻāĻā§āϰāϤāĻžāϰ āĻāĻĒāϰāĨ¤
- āĻā§āώāϤ āĻāϤāĻāĻž contaminatedāĨ¤
- Foreign Body āĻ āĻŦāĻļāĻŋāώā§āĻ āĻāĻā§ āĻāĻŋ āύāĻžāĨ¤
- Infection-āĻāϰ clinical evidenceāĨ¤
- Patient risk factorsāĨ¤
Clinical Assessment: Polycef-āĻāϰ āĻŦā§āϝāĻŦāĻšāĻžāϰ āϏāĻŽā§āĻāĻžāĻŦā§āϝāĻāĻžāĻŦā§ āϝā§āĻā§āϤāĻŋāϏāĻāĻāϤ, āĻāĻŋāύā§āϤ⧠āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύ⧠confirmed bacterial infection-āĻāϰ āĻĒā§āϰāĻŽāĻžāĻŖ āύā§āĻāĨ¤
Confidence in likely prescribing purpose: 0.85
Bangladesh Available Alternative Brands
| Brand | Company | Generic |
|---|---|---|
| Lebac 500 | Square | Cephradine |
| Procef 500 | Incepta | Cephradine |
| Intracef 500 | Beximco | Cephradine |
| Polycef 500 | Renata | Cephradine |
| Rocef 500 | Healthcare | Cephradine |
Precaution: Cephalosporin allergy āĻāĻŦāĻ renal impairment āĻĨāĻžāĻāϞ⧠āϏāϤāϰā§āĻāϤāĻž āĻĒā§āϰā§ā§āĻāύāĨ¤
Drug No. 4 â Tab. Solivo 500 mg
Corrected Medicine Identification
Brand Name: Solivo 500 mg + 20 mg
Generic Name: Naproxen Sodium + Esomeprazole Magnesium
Manufacturer: Healthcare Pharmaceuticals Ltd.
Dosage Form: Delayed Release Tablet
Correct Composition
| Active Ingredient | Strength |
|---|---|
| Naproxen Sodium | 500 mg |
| Esomeprazole Magnesium | 20 mg |
āĻ āϰā§āĻĨāĻžā§ Solivo 500 āĻšāϞ⧠āĻāĻāĻāĻŋ combination medicine; āĻļā§āϧ⧠Naproxen 500 mg āύā§āĨ¤
MedEx Therapeutic Class
MedEx āĻ āύā§āϝāĻžā§ā§:
Drugs for Osteoarthritis, Drugs used for Rheumatoid Arthritis, Non-steroidal Anti-inflammatory Drugs (NSAIDs).
Pharmacological Class
āĻĻā§āĻāĻŋ āĻāĻĒāĻžāĻĻāĻžāύā§āϰ pharmacological class āĻāϞāĻžāĻĻāĻžāĨ¤
1. Naproxen Sodium
- Non-steroidal Anti-inflammatory Drug (NSAID)
- Analgesic
- Anti-inflammatory Agent
- Antipyretic
2. Esomeprazole Magnesium
- Proton Pump Inhibitor (PPI)
- Gastric Acid Secretion Inhibitor
Price According to MedEx
| Presentation | Price |
|---|---|
| Unit Price | ā§ŗ15.00 |
| Strip Price (6 tablets) | ā§ŗ90.00 |
| Pack Price (30 tablets) | ā§ŗ450.00 |
Other Available Composition
Solivo 375 mg + 20 mg
Unit Price: ā§ŗ13.00
MedEx Link: Solivo 500 mg + 20 mg â MedEx
Mechanism of Action
Naproxen: COX-mediated prostaglandin synthesis āĻāĻŽāĻŋā§ā§ pain āĻ inflammation āĻāĻĒāĻļāĻŽ āĻāϰā§āĨ¤
Esomeprazole: Gastric parietal cell-āĻāϰ proton pump inhibit āĻāϰ⧠gastric acid secretion āĻāĻŽāĻžā§āĨ¤
Use of Purpose the Drug
MedEx-āĻāϰ labelled indications āĻ āύā§āϝāĻžā§ā§ āĻāĻāĻŋ āĻŽā§āϞāϤ āĻŦā§āϝāĻŦāĻšā§āϤ āĻšā§:
- Osteoarthritis â āĻ āϏā§āĻĨāĻŋāϏāύā§āϧāĻŋāϰ āĻā§āώā§āĻāύāĻŋāϤ āĻŦā§āϝāĻĨāĻž āĻ āĻĒā§āϰāĻĻāĻžāĻšāĨ¤
- Rheumatoid Arthritis â āĻĒā§āϰāĻĻāĻžāĻšāĻāύāĻŋāϤ āĻŦāĻžāϤāĨ¤
- Ankylosing Spondylitis â āĻŽā§āϰā§āĻĻāĻŖā§āĻĄā§āϰ āĻĒā§āϰāĻĻāĻžāĻšāĻāύāĻŋāϤ āĻŦāĻžāϤāĨ¤
- NSAID-associated Gastric Ulcer Risk Reduction â NSAID-āϏāĻŽā§āĻĒāϰā§āĻāĻŋāϤ āĻĒāĻžāĻāϏā§āĻĨāϞā§āϰ āĻāϞāϏāĻžāϰā§āϰ āĻā§āĻāĻāĻŋ āĻāĻŽāĻžāύā§āĨ¤
Why Doctor Prescribed Solivo in This Patient
āĻāĻ āϰā§āĻā§āϰ āĻā§āώā§āϤā§āϰ⧠āϏāĻŽā§āĻāĻŦāϤ āĻāĻāĻžāϤāĻāύāĻŋāϤ āĻŦā§āϝāĻĨāĻž āĻāĻŦāĻ āϏā§āĻĨāĻžāύā§ā§ inflammation āĻāĻŽāĻžāύā§āϰ āĻāĻĻā§āĻĻā§āĻļā§āϝ⧠Solivo āĻĻā§āĻā§āĻž āĻšā§ā§āĻā§āĨ¤
Naproxen-āĻāϰ āĻāĻĻā§āĻĻā§āĻļā§āϝ: Injury-related pain āĻ inflammatory response āύāĻŋā§āύā§āϤā§āϰāĻŖ āĻāϰāĻžāĨ¤
Esomeprazole-āĻāϰ āĻāĻĻā§āĻĻā§āĻļā§āϝ: Naproxen-āĻāϰ āĻāĻžāϰāĻŖā§ gastric acid-related complication āĻ ulcer-āĻāϰ āĻā§āĻāĻāĻŋ āĻāĻŽāĻžāύā§āĨ¤
āĻāĻāĻŋ āϰā§āĻā§āϰ āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ āĻā§āώā§āϤā§āϰ⧠āϏāĻŽā§āĻāĻžāĻŦā§āϝ prescribing rationaleāĨ¤ āϤāĻŦā§ traumatic wound pain, Solivo combination-āĻāϰ āĻĒā§āϰāϧāĻžāύ labelled indication āύā§āĨ¤
Clinical Justification
Penetrating injury-āĻāϰ āĻĒāϰ⧠āĻŦā§āϝāĻĨāĻž āĻšāϤ⧠āĻĒāĻžāϰā§āĨ¤
āϤāĻžāĻ analgesic āĻŦā§āϝāĻŦāĻšāĻžāϰ āϝā§āĻā§āϤāĻŋāϝā§āĻā§āϤ āĻšāϤ⧠āĻĒāĻžāϰā§āĨ¤
āĻāĻŋāύā§āϤ⧠NSAID āĻŦā§āϝāĻŦāĻšāĻžāϰā§āϰ āĻāĻā§ āϰā§āĻā§āϰ bleeding risk, renal function, peptic ulcer history, cardiovascular disease āĻāĻŦāĻ āĻ āύā§āϝāĻžāύā§āϝ āĻāώā§āϧ āĻŦāĻŋāĻŦā§āĻāύāĻž āĻāϰāϤ⧠āĻšāĻŦā§āĨ¤
Important Precautions
Solivo āĻŦā§āϝāĻŦāĻšāĻžāϰ āϏāϤāϰā§āĻāϤāĻžāϰ āĻĒā§āϰā§ā§āĻāύ:
- Peptic Ulcer DiseaseāĨ¤
- Gastrointestinal BleedingāĨ¤
- Renal ImpairmentāĨ¤
- NSAID HypersensitivityāĨ¤
- Anticoagulant UseāĨ¤
- Significant Cardiovascular DiseaseāĨ¤
- Pregnancy, particularly third trimesterāĨ¤
Esomeprazole āĻĒāĻžāĻāϏā§āĻĨāϞā§āϰ āĻāĻŋāĻā§ āĻā§āĻāĻāĻŋ āĻāĻŽāĻžāϞā§āĻ Naproxen-āĻāϰ kidney, cardiovascular āĻŦāĻž bleeding-related āϏāĻŦ āĻā§āĻāĻāĻŋ āĻĻā§āϰ āĻāϰ⧠āύāĻžāĨ¤
Clinical Confidence in prescribing purpose: 0.90
Bangladesh Alternative Brands â Same Composition
| Brand | Company | Composition |
|---|---|---|
| Xenole | Square | 500 mg + 20 mg |
| Dinovo | Beximco | 500 mg + 20 mg |
| Progesic | Incepta | 500 mg + 20 mg |
| Progut-N | Popular | 500 mg + 20 mg |
| Solivo | Healthcare | 500 mg + 20 mg |
āĻāĻ brand-āĻā§āϞ⧠āĻāĻāĻ generic combination-āĻāϰ āĻāĻĻāĻžāĻšāϰāĻŖāĨ¤ Prescribed brand āĻĒāϰāĻŋāĻŦāϰā§āϤāύā§āϰ āĻāĻā§ āĻāĻŋāĻāĻŋā§āϏāĻā§āϰ āĻ āύā§āĻŽā§āĻĻāύ āĻĒā§āϰā§ā§āĻāύāĨ¤
Drug No. 5 â Viodin Wash
Corrected Identification
Brand Name: Viodin
Generic Name: Povidone Iodine
Manufacturer: Square Pharmaceuticals PLC
Likely Preparation: Viodin 10% w/v Solution
āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύ⧠concentration āϏā§āĻĒāώā§āĻāĻāĻžāĻŦā§ āϞā§āĻāĻž āύā§āĻāĨ¤ āϤāĻžāĻ 10% Solution-āĻā§ āϏāĻŦāĻā§ā§ā§ āĻĒā§āϰāĻžāϏāĻā§āĻāĻŋāĻ marketed preparation āĻšāĻŋāϏā§āĻŦā§ āĻĻā§āĻāĻžāύ⧠āĻšā§ā§āĻā§āĨ¤
MedEx Therapeutic Class
Iodine Compounds (Anti-septic Preparations)
Pharmacological Class
Topical Antiseptic / Iodophor Antimicrobial Agent
Available Compositions
| Preparation | Strength |
|---|---|
| Viodin Solution | 10% w/v |
| Viodin Ointment | 5% w/w |
| Viodin Mouthwash | 1% w/v |
āĻāĻ āϰā§āĻā§āϰ wound care-āĻāϰ āĻāύā§āϝ Mouthwash āύā§, Solution formulation āĻĒā§āϰāĻžāϏāĻā§āĻāĻŋāĻāĨ¤
Unit Price and Pack Price
| Presentation | Price |
|---|---|
| 15 ml Solution | ā§ŗ30 |
| 100 ml Solution | ā§ŗ120 |
| 1000 ml Solution | ā§ŗ800 |
MedEx Link: Viodin 10% Solution â MedEx
Mechanism of Action
Povidone Iodine āĻāĻāĻāĻŋ broad-spectrum antisepticāĨ¤
āĻāĻāĻŋ āϧā§āϰ⧠āϧā§āϰ⧠free iodine release āĻāϰ⧠āĻŦāĻŋāĻāĻŋāύā§āύ āĻ āĻŖā§āĻā§āĻŦā§āϰ protein āĻ āĻ āύā§āϝāĻžāύā§āϝ cellular component āĻā§āώāϤāĻŋāĻā§āϰāϏā§āϤ āĻāϰā§āĨ¤
āĻāĻāĻŋ āĻ āύā§āĻ bacteria, fungi āĻ virus-āĻāϰ āĻŦāĻŋāϰā§āĻĻā§āϧ⧠āĻāĻžāϰā§āϝāĻāϰāĨ¤
Use of Purpose the Drug
Viodin-āĻāϰ āĻŦā§āϝāĻŦāĻšāĻžāϰāĻā§āϞā§āϰ āĻŽāϧā§āϝ⧠āϰā§ā§āĻā§:
- Wound Antisepsis: āĻā§āώāϤāϏā§āĻĨāĻžāύ⧠āĻā§āĻŦāĻžāĻŖā§āϰ āĻĒāϰāĻŋāĻŽāĻžāĻŖ āĻāĻŽāĻžāύā§āĨ¤
- Preoperative Skin Preparation: āĻ āϏā§āϤā§āϰā§āĻĒāĻāĻžāϰā§āϰ āĻāĻā§ āϤā§āĻŦāĻ antisepsisāĨ¤
- Postoperative Wound Care: āĻĒā§āϰā§ā§āĻāύāĻŽāϤ⧠postoperative wound antisepsisāĨ¤
- Minor Cuts and Abrasions: āĻā§āĻ āĻāĻžāĻāĻž āĻŦāĻž āĻā§ā§ āϝāĻžāĻā§āĻž āĻā§āώāϤ⧠topical antiseptic āĻšāĻŋāϏā§āĻŦā§ āĻŦā§āϝāĻŦāĻšāĻžāϰāĨ¤
Why Doctor Prescribed Viodin in This Patient
āĻāĻŋāĻāĻŋā§āϏāĻ Debridement āĻāĻŦāĻ Foreign Body Removal-āĻāϰ āϏāĻā§āĻā§ wound antisepsis-āĻāϰ āĻāύā§āϝ Viodin wash āĻāϞā§āϞā§āĻ āĻāϰā§āĻā§āύāĨ¤
āϏāĻŽā§āĻāĻžāĻŦā§āϝ āĻāĻĻā§āĻĻā§āĻļā§āϝ:
- āĻā§āώāϤāϏā§āĻĨāĻžāύā§āϰ āĻāĻļāĻĒāĻžāĻļā§ microbial contamination āĻāĻŽāĻžāύā§āĨ¤
- Surgical wound preparationāĨ¤
- Dressing-āĻāϰ āĻāĻā§ āĻāĻĒāϝā§āĻā§āϤ topical antiseptic careāĨ¤
Is Viodin Suitable for Debridement?
Viodin āύāĻŋāĻā§ Debridement āĻāϰ⧠āύāĻžāĨ¤
Debridement-āĻ dead tissue āĻ foreign material āĻ āĻĒāϏāĻžāϰāĻŖ āĻāϰāĻž āĻšā§āĨ¤
Viodin wound antisepsis-āĻāϰ āϏāĻšāĻžā§āĻ āĻāĻĒāĻžāĻĻāĻžāύāĨ¤
AAFP-āĻāϰ evidence review āĻ āύā§āϝāĻžā§ā§ foreign-body wound āĻĒāϰāĻŋāώā§āĻāĻžāϰ⧠normal saline āĻŦāĻž potable water āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻāϰāĻž āϝāĻžā§, āĻāĻŦāĻ deep wound irrigation-āĻ antiseptic solution āϏāĻžāϧāĻžāϰāĻŖāϤ āĻā§āĻŋā§ā§ āĻāϞāĻž āĻāĻāĻŋāϤāĨ¤
Important Precaution
- Deep puncture wound-āĻ āĻāĻŋāĻāĻŋā§āϏāĻā§āϰ āϤāϤā§āϤā§āĻŦāĻžāĻŦāϧāĻžāύ āĻāĻžā§āĻž concentrated solution āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻāϰāĻž āĻāĻāĻŋāϤ āύā§āĨ¤
- Povidone-iodine hypersensitivity āĻĨāĻžāĻāϞ⧠āϏāϤāϰā§āĻāϤāĻž āĻĒā§āϰā§ā§āĻāύāĨ¤
- Thyroid disorder, significant renal impairment āĻ āĻĨāĻŦāĻž āĻŦā§ āĻā§āώāϤāϏā§āĻĨāĻžāύ⧠repeated use-āĻāϰ āĻā§āώā§āϤā§āϰ⧠āĻŦāĻŋāĻļā§āώ āϏāϤāϰā§āĻāϤāĻž āĻĒā§āϰā§ā§āĻāύāĨ¤
Clinical Confidence in intended purpose: 0.95
8. Differential Diagnosis â āϏāĻŽā§āĻāĻžāĻŦā§āϝ āϰā§āĻāϏāĻŽā§āĻš
| Diagnosis | āĻŦāĻžāĻāϞāĻž āĻ āϰā§āĻĨ | Clinical Assessment |
|---|---|---|
| Penetrating Soft-Tissue Injury | āύāϰāĻŽ āĻāĻŋāϏā§āϝā§āϤ⧠āϧāĻžāϰāĻžāϞ⧠āĻŦāϏā§āϤā§āϰ āĻāĻāĻžāϤ | Strongly supported |
| Foreign Body Impaction | āĻāĻŋāϏā§āϝā§āϰ āĻŽāϧā§āϝ⧠āĻŦāĻžāĻāϰā§āϰ āĻŦāϏā§āϤ⧠āĻāĻāĻā§ āϝāĻžāĻā§āĻž | Strongly supported |
| Contaminated Traumatic Wound | āĻĻā§āώāĻŋāϤ āĻšāĻā§āĻžāϰ āϏāĻŽā§āĻāĻžāĻŦāύāĻžāϝā§āĻā§āϤ āĻāĻāĻžāϤ | Supported |
| Localized Wound Infection | āϏā§āĻĨāĻžāύā§ā§ āĻā§āώāϤā§āϰ āϏāĻāĻā§āϰāĻŽāĻŖ | Not confirmed |
| Soft-Tissue Abscess | āύāϰāĻŽ āĻāĻŋāϏā§āϝā§āϤ⧠āĻĒā§āĻāĻ āĻāĻŽāĻž | Not confirmed |
| Tendon Injury | āĻā§āύā§āĻĄāύā§āϰ āĻāĻāĻžāϤ | Examination required |
| Neurovascular Injury | āϏā§āύāĻžā§ā§ āĻŦāĻž āϰāĻā§āϤāύāĻžāϞāĻŋāϰ āĻāĻāĻžāϤ | Examination required |
Clinical Interpretation
āϏāĻŦāĻā§ā§ā§ āĻā§āϰā§āϤā§āĻŦāĻĒā§āϰā§āĻŖ diagnosis āĻšāϞ⧠Foreign Body ImpactionāĨ¤
āĻļā§āϧ⧠rusty material-āĻāϰ āĻāϤāĻŋāĻšāĻžāϏ āĻĨāĻžāĻāĻžā§ āϰā§āĻā§āĻā§ Tetanus Patient āĻŦāϞāĻž āϝāĻžāĻŦā§ āύāĻžāĨ¤
Tetanus prophylaxis āĻĻā§āĻā§āĻžāϰ āĻ āϰā§āĻĨ āĻšāϞ⧠āϰā§āĻ āĻĒā§āϰāϤāĻŋāϰā§āϧā§āϰ āĻŦā§āϝāĻŦāϏā§āĻĨāĻž āύā§āĻā§āĻž; āϰā§āĻā§ āĻāϤāĻŋāĻŽāϧā§āϝ⧠tetanus-āĻ āĻāĻā§āϰāĻžāύā§āϤâāĻāĻŽāύ āύā§āĨ¤
9. My Clinical Working Assessment
āĻāĻŽāĻžāϰ āĻā§ā§āĻžāύā§āϤ āĻā§āϞāĻŋāύāĻŋāĻā§āϝāĻžāϞ āĻŽā§āϞā§āϝāĻžā§āύ
Primary Working Diagnosis
Traumatic Penetrating Soft-Tissue Injury with Foreign Body Impaction, involving Rust-Contaminated Material.
āĻŦāĻžāĻāϞāĻž āϰā§āĻāύāĻŋāϰā§āĻŖā§
āĻĻā§āϰā§āĻāĻāύāĻžāĻāύāĻŋāϤ āĻāĻāĻžāϤ⧠āĻŽāϰāĻŋāĻāĻžāϝā§āĻā§āϤ āĻŦāĻžāĻāϰā§āϰ āĻā§āύ⧠āĻŦāϏā§āϤ⧠āύāϰāĻŽ āĻāĻŋāϏā§āϝā§āϰ āĻŽāϧā§āϝ⧠āĻĒā§āϰāĻŦā§āĻļ āĻāϰ⧠āĻāĻāĻā§ āϝāĻžāĻā§āĻžāϰ āĻāϤāĻŋāĻšāĻžāϏāĨ¤
Pathophysiological Assessment
Foreign Body Penetration-āĻāϰ āĻāĻžāϰāĻŖā§ āϏā§āĻĨāĻžāύā§ā§ tissue injury āĻāĻŦāĻ inflammatory response āϏā§āώā§āĻāĻŋ āĻšāϤ⧠āĻĒāĻžāϰā§āĨ¤
āĻā§āώāϤā§āϰ āĻŽāϧā§āϝ⧠Foreign Body āĻ āĻŦāĻļāĻŋāώā§āĻ āĻĨāĻžāĻāϞā§:
- Inflammation āĻĻā§āϰā§āĻāϏā§āĻĨāĻžā§ā§ āĻšāϤ⧠āĻĒāĻžāϰā§āĨ¤
- Persistent pain āĻšāϤ⧠āĻĒāĻžāϰā§āĨ¤
- Secondary bacterial infection-āĻāϰ āĻā§āĻāĻāĻŋ āĻŦāĻžā§āϤ⧠āĻĒāĻžāϰā§āĨ¤
- Granulomatous reaction āĻšāϤ⧠āĻĒāĻžāϰā§āĨ¤
- Abscess formation āĻšāϤ⧠āĻĒāĻžāϰā§āĨ¤
āϤāĻŦā§ āĻŦāϰā§āϤāĻŽāĻžāύ āϰā§āĻā§āϰ āĻā§āώā§āϤā§āϰ⧠āĻāĻā§āϞā§āϰ āĻā§āύā§āĻāĻŋ āύāĻŋāĻļā§āĻāĻŋāϤāĻāĻžāĻŦā§ āĻāĻĒāϏā§āĻĨāĻŋāϤ āĻāĻā§ āĻŦāϞ⧠āĻĻāĻžāĻŦāĻŋ āĻāϰāĻž āϝāĻžāĻā§āĻā§ āύāĻžāĨ¤
Clinical Confidence Assessment
| Clinical Finding | Confidence |
|---|---|
| History of accidental injury | 0.95 |
| History involving rusty material | 0.95 |
| Foreign Body Impaction at original presentation | 0.95 |
| Penetrating Soft-Tissue Injury | 0.90 |
| Current Retained Foreign Body | Cannot determine |
| Active Bacterial Infection | Insufficient evidence |
| Soft-Tissue Abscess | Insufficient evidence |
| Clinical Tetanus | No supporting evidence |
Final Assessment
āĻŽā§āϞ āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύā§āϰ āĻāĻŋāϤā§āϤāĻŋāϤ⧠āĻāĻŋāĻāĻŋā§āϏāĻā§āϰ Diagnosis āϝāĻĨāĻžāϝāĻĨāĻāĻžāĻŦā§ Foreign Body Impaction āĻšāĻŋāϏā§āĻŦā§ āĻŦā§āϝāĻžāĻā§āϝāĻž āĻāϰāĻž āϝāĻžā§āĨ¤
āĻāĻāĻžāύ⧠āϏāĻŦāĻā§ā§ā§ āĻā§āϰā§āϤā§āĻŦāĻĒā§āϰā§āĻŖ āĻŦāĻŋāώ⧠āĻšāĻā§āĻā§ Foreign Body Management, Wound Assessment āĻāĻŦāĻ Tetanus ProphylaxisāĨ¤
10. Doctor's Diagnosis vs My Diagnosis
| Comparison | Treating Doctor | My Assessment |
|---|---|---|
| Primary Diagnosis | FB Impaction | Penetrating Injury with FB Impaction |
| Injury Mechanism | Accidental | Accidental |
| Material | Rusty Materials | Rust-contaminated material |
| Infection Status | Not specified | Not confirmed |
| Foreign Body Removal | Advised | Assess need and confirm completion |
| Wound Care | Debridement and Viodin Wash | Irrigation, debridement and appropriate antisepsis |
| Tetanus Prophylaxis | Vaxitet + IG noted | Vaccination history-based assessment required |
Are the Diagnoses Similar?
āĻšā§āϝāĻžāĻāĨ¤ āĻŽā§āϞ āϰā§āĻāύāĻŋāϰā§āĻŖā§ā§āϰ āĻā§āώā§āϤā§āϰ⧠āĻāĻŋāĻāĻŋā§āϏāĻā§āϰ Diagnosis āĻāĻŦāĻ āĻāĻŽāĻžāϰ Clinical Working Diagnosis āĻāĻāĻ āϏāĻŽāϏā§āϝāĻžāĻā§ āύāĻŋāϰā§āĻĻā§āĻļ āĻāϰā§āĨ¤
āϤāĻŦā§ āĻāĻŽāĻžāϰ Diagnosis-āĻ āĻāĻāĻžāϤā§āϰ āϧāϰāύ, contamination risk āĻāĻŦāĻ diagnostic uncertainty āĻāϞāĻžāĻĻāĻž āĻāϰ⧠āĻāϞā§āϞā§āĻ āĻāϰāĻž āĻšā§ā§āĻā§āĨ¤
Important Difference
āĻāĻŋāĻāĻŋā§āϏāĻā§āϰ Diagnosis āĻšāϞā§:
FB Impaction
āĻāĻŽāĻžāϰ āĻāϰāĻ āĻŦāĻŋāϏā§āϤāĻžāϰāĻŋāϤ assessment āĻšāϞā§:
Traumatic Penetrating Soft-Tissue Injury with Foreign Body Impaction.
āĻā§āύ⧠confirmed infection, abscess āĻŦāĻž tetanus āϝā§āĻ āĻāϰāĻž āĻšā§āύāĻŋāĨ¤
Estimated diagnostic agreement confidence: 0.90
āĻāĻ confidence āĻāĻāĻāĻŋ clinical judgement, āĻĒāϰā§āĻā§āώāĻžā§ āĻĒāϰāĻŋāĻŽāĻžāĻĒ āĻāϰāĻž statistical accuracy āύā§āĨ¤
11. Investigations â āĻĒā§āϰā§ā§āĻāύā§ā§ āĻĒāϰā§āĻā§āώāĻž
Doctor’s Prescribed Investigations
āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύ⧠āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ āĻā§āύ⧠investigation āϏā§āĻĒāώā§āĻāĻāĻžāĻŦā§ āϞā§āĻāĻž āύā§āĻāĨ¤
My Recommended Investigations
āĻĒāϰā§āĻā§āώāĻžāĻā§āϞ⧠āĻā§āώāϤā§āϰ āĻŦāϰā§āϤāĻŽāĻžāύ āĻ āĻŦāϏā§āĻĨāĻžāϰ āĻāĻĒāϰ āύāĻŋāϰā§āĻāϰ āĻāϰāĻŦā§āĨ¤
| Investigation | Why Needed | Priority |
|---|---|---|
| X-ray of Affected Area | Metal Foreign Body āĻļāύāĻžāĻā§āϤ āĻāϰāĻž | High if retention suspected |
| Soft-Tissue Ultrasound | Foreign Body localization āĻ āĻĨāĻŦāĻž collection āĻļāύāĻžāĻā§āϤ āĻāϰāĻž | Conditional |
| CBC | āĻāϞā§āϞā§āĻāϝā§āĻā§āϝ āϏāĻāĻā§āϰāĻŽāĻŖ āϏāύā§āĻĻā§āĻš āĻšāϞ⧠| Conditional |
| CRP | āĻāĻāĻŋāϞ āϏāĻāĻā§āϰāĻŽāĻŖā§āϰ āĻŽā§āϞā§āϝāĻžā§āύ⧠āϏāĻšāĻžā§āĻ | Conditional |
| Blood Glucose | Diabetes āĻŦāĻž healing problem āϏāύā§āĻĻā§āĻš āĻšāϞ⧠| Conditional |
| Pus Culture and Sensitivity | Purulent āĻŦāĻž complicated infection āĻĨāĻžāĻāϞ⧠| Conditional |
| CT Scan | Deep-seated FB āĻŦāĻž āĻāĻāĻŋāϞ anatomical involvement | Selected cases |
Why X-ray Is Important
Metal āϏāĻžāϧāĻžāϰāĻŖāϤ radiopaqueāĨ¤
āϤāĻžāĻ āĻā§āώāϤā§āϰ āĻŽāϧā§āϝ⧠āϧāĻžāϤāĻŦ āĻŦāϏā§āϤ⧠āĻāĻāĻā§ āĻĨāĻžāĻāĻžāϰ āϏāύā§āĻĻā§āĻš āĻĨāĻžāĻāϞ⧠X-ray āĻāĻāĻāĻŋ āĻāĻĒāϝā§āĻā§āϤ initial investigationāĨ¤
Ultrasound āĻĻāĻŋā§ā§ āύāĻŋāϰā§āĻĻāĻŋāώā§āĻ āĻāĻŋāĻā§ Foreign Body āĻāĻŦāĻ surrounding soft-tissue abnormalities āĻļāύāĻžāĻā§āϤ āĻāϰāĻž āϝāĻžā§āĨ¤
12. Bangladesh Doctors Commonly Used Drugs
āĻāĻ āϧāϰāύā§āϰ Penetrating Injury āĻ Foreign Body Wound-āĻ āĻŦā§āϝāĻŦāĻšā§āϤ āĻāώā§āϧā§āϰ āĻāĻĻāĻžāĻšāϰāĻŖ
āϏāĻŦ āϰā§āĻā§āϰ āĻāύā§āϝ āĻāĻāĻ āĻāώā§āϧ āĻĒā§āϰāϝā§āĻā§āϝ āύā§āĨ¤ āϏāĻāĻā§āϰāĻŽāĻŖā§āϰ āĻāĻĒāϏā§āĻĨāĻŋāϤāĻŋ, wound contamination, tetanus vaccination status āĻāĻŦāĻ āϰā§āĻā§āϰ āĻ āύā§āϝāĻžāύā§āϝ āĻā§āĻāĻāĻŋ āĻ āύā§āϝāĻžā§ā§ āĻāĻŋāĻāĻŋā§āϏāĻž āĻāϞāĻžāĻĻāĻž āĻšā§āĨ¤
1. Tetanus Vaccine
Generic: Adsorbed Tetanus Vaccine** ** Brand: Vaxitet, TTvax** ** Purpose: Tetanus preventionāĨ¤
2. Human Tetanus Immunoglobulin
Generic: Human Tetanus Immunoglobulin** ** Brand: Protet-IG, Tetagam-P** ** Purpose: Dirty wound-āĻāϰ āĻā§āώā§āϤā§āϰ⧠vaccination history āĻ āύā§āϝāĻžā§ā§ āĻĒā§āϰā§ā§āĻāύ āĻšāϞ⧠passive protectionāĨ¤
3. Cephradine
Brand: Polycef, Lebac, Procef** ** Therapeutic Class: First Generation Cephalosporins** ** Purpose: Susceptible bacterial soft-tissue infectionāĨ¤
4. Flucloxacillin
Brand Example: A-Flox** ** Pharmacological Class: Penicillinase-resistant Penicillin** ** Purpose: āύāĻŋāϰā§āĻŦāĻžāĻāĻŋāϤ staphylococcal skin and soft-tissue infectionāĨ¤
5. Naproxen Sodium + Esomeprazole
Brand: Solivo, Xenole, Dinovo** ** Purpose: Pain āĻ inflammation āύāĻŋā§āύā§āϤā§āϰāĻŖā§āϰ āĻā§āώā§āϤā§āϰ⧠āύāĻŋāϰā§āĻŦāĻžāĻāĻŋāϤ āĻŦā§āϝāĻŦāĻšāĻžāϰ; Esomeprazole NSAID-related gastric ulcer risk āĻāĻŽāĻžāϤ⧠āϏāĻžāĻšāĻžāϝā§āϝ āĻāϰā§āĨ¤
6. Paracetamol
Brand: Napa 500 mg** ** Generic: Paracetamol** ** Purpose: Mild-to-moderate pain āĻ āĻĨāĻŦāĻž fever managementāĨ¤
MedEx Price: ā§ŗ1.20 per tablet; ā§ŗ12.00 per 10-tablet stripāĨ¤
MedEx Link: Napa 500 mg â MedEx
7. Povidone Iodine
Brand: Viodin, Betadine** ** Pharmacological Class: Topical Antiseptic** ** Purpose: āĻāĻĒāϝā§āĻā§āϤ wound antisepsisāĨ¤
Clinical Caution
Antibiotic-āĻā§āϞ⧠āĻāĻāϏāĻā§āĻā§ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻāϰāĻžāϰ āϤāĻžāϞāĻŋāĻāĻž āύā§āĨ¤ uncomplicated wound-āĻ antibiotic āĻĒā§āϰā§ā§āĻāύ āύāĻžāĻ āĻšāϤ⧠āĻĒāĻžāϰā§; contaminated āĻ āĻĨāĻŦāĻž high-risk wound-āĻ antibiotic prophylaxis āĻŦāĻŋāĻŦā§āĻāύāĻž āĻāϰāĻž āϝāĻžā§āĨ¤
13. Doctor's Actionable Management Plan
Step 1 â Assess the Wound
āĻā§āώāϤā§āϰ āϏā§āĻĨāĻžāύ, āĻāĻā§āϰāϤāĻž, contamination, tenderness āĻāĻŦāĻ neurovascular status āĻŽā§āϞā§āϝāĻžā§āύ āĻāϰāϤ⧠āĻšāĻŦā§āĨ¤
Step 2 â Investigate Retained Foreign Body
Foreign Body āĻ āĻŦāĻļāĻŋāώā§āĻ āĻĨāĻžāĻāĻžāϰ āϏāύā§āĻĻā§āĻš āĻĨāĻžāĻāϞ⧠X-ray āĻ āĻĨāĻŦāĻž āĻāĻĒāϝā§āĻā§āϤ imaging āĻāϰāϤ⧠āĻšāĻŦā§āĨ¤
Step 3 â Foreign Body Removal
Foreign Body āĻĨāĻžāĻāϞ⧠āĻ āĻŦāϏā§āĻĨāĻžāύ āĻāĻŦāĻ anatomical risk āĻ āύā§āϝāĻžā§ā§ removal-āĻāϰ āϏāĻŋāĻĻā§āϧāĻžāύā§āϤ āύāĻŋāϤ⧠āĻšāĻŦā§āĨ¤
Deeply embedded object, tendon, nerve āĻŦāĻž blood vessel-āĻāϰ āĻāĻžāĻāĻžāĻāĻžāĻāĻŋ āĻĨāĻžāĻāϞ⧠specialist removal āĻĒā§āϰā§ā§āĻāύ āĻšāϤ⧠āĻĒāĻžāϰā§āĨ¤
Step 4 â Wound Irrigation and Debridement
āĻā§āώāϤ āĻĒāϰāĻŋāώā§āĻāĻžāϰ āĻāϰāϤ⧠āĻšāĻŦā§ āĻāĻŦāĻ devitalized tissue āĻĨāĻžāĻāϞ⧠āĻĒā§āϰā§ā§āĻāύāĻŽāϤ⧠debridement āĻāϰāϤ⧠āĻšāĻŦā§āĨ¤
Normal saline irrigation āϏāĻžāϧāĻžāϰāĻŖāϤ āĻāĻĒāϝā§āĻā§āϤāĨ¤
Viodin āĻĒā§āϰā§ā§āĻāύāĻŽāϤ⧠surrounding skin antisepsis-āĻāϰ āĻāύā§āϝ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻāϰāĻž āϝā§āϤ⧠āĻĒāĻžāϰā§āĨ¤
Step 5 â Review Tetanus Protection
Vaccination history āϝāĻžāĻāĻžāĻ āĻāϰāϤ⧠āĻšāĻŦā§āĨ¤
āĻĒā§āϰā§ā§āĻāύ āĻšāϞ⧠guideline āĻ āύā§āϝāĻžā§ā§ vaccine āĻāĻŦāĻ Human TIG āĻĻāĻŋāϤ⧠āĻšāĻŦā§āĨ¤
Step 6 â Assess Antibiotic Requirement
Infection āĻ āĻĨāĻŦāĻž high-risk wound-āĻāϰ clinical evidence āĻĨāĻžāĻāϞ⧠appropriate antibiotic āύāĻŋāϰā§āĻŦāĻžāĻāύ āĻāϰāϤ⧠āĻšāĻŦā§āĨ¤
āĻļā§āϧ⧠āĻāĻŋāĻā§āύāĻžāϏ āĻĒā§āϰāϤāĻŋāϰā§āϧā§āϰ āĻāĻĻā§āĻĻā§āĻļā§āϝ⧠antibiotic āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻāϰāĻž āĻāĻāĻŋāϤ āύā§āĨ¤
Step 7 â Pain Management
āĻŦā§āϝāĻĨāĻžāϰ āϤā§āĻŦā§āϰāϤāĻž āĻ āϰā§āĻā§āϰ contraindication āĻ āύā§āϝāĻžā§ā§ analgesic āύāĻŋāϰā§āĻŦāĻžāĻāύ āĻāϰāϤ⧠āĻšāĻŦā§āĨ¤
Solivo āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻāϰāϞ⧠NSAID-related gastrointestinal, renal āĻāĻŦāĻ bleeding risks āĻŽā§āϞā§āϝāĻžā§āύ āĻāϰāϤ⧠āĻšāĻŦā§āĨ¤
Step 8 â Follow-up
Foreign Body Removal āϏāĻŽā§āĻĒāύā§āύ āĻšā§ā§āĻā§ āĻāĻŋ āύāĻž āύāĻŋāĻļā§āĻāĻŋāϤ āĻāϰāϤ⧠āĻšāĻŦā§āĨ¤
Persistent pain, swelling, discharge, fever āĻŦāĻž impaired movement āĻĨāĻžāĻāϞ⧠āĻĒā§āύāϰā§āĻŽā§āϞā§āϝāĻžā§āύ āĻĒā§āϰā§ā§āĻāύāĨ¤
Important: āĻāĻ āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύāĻāĻŋ ⧍ā§Ļā§¨ā§Š āϏāĻžāϞā§āϰ āĻšāϞ⧠āĻāĻĒāϰā§āĻā§āϤ plan āĻĒā§āϰā§āύ⧠āĻāĻŋāĻāĻŋā§āϏāĻž-āĻāĻāύāĻžāϰ āĻŦāĻŋāĻļā§āϞā§āώāĻŖ āĻšāĻŋāϏā§āĻŦā§ āĻĒā§āϰāϝā§āĻā§āϝāĨ¤ ⧍ā§Ļ⧍ā§Ŧ āϏāĻžāϞ⧠āϰā§āĻā§āϰ āĻŦāϰā§āϤāĻŽāĻžāύ āĻ āĻŦāϏā§āĻĨāĻž āύāĻž āĻā§āύ⧠āύāϤā§āύ āĻāϰ⧠āĻāĻāĻ āĻāώā§āϧ āĻļā§āϰ⧠āĻāϰāĻž āĻāĻāĻŋāϤ āύā§āĨ¤
14. Referral â āĻā§āύ āĻŦāĻŋāĻļā§āώāĻā§āĻā§āϰ āĻāĻžāĻā§ āĻĒāĻžāĻ āĻžāĻŦā§āύ?
Primary Referral
General Surgeon â āĻā§āύāĻžāϰā§āϞ āϏāĻžāϰā§āĻāύ
Reason for Referral
- Foreign Body Evaluation
- Surgical Exploration
- Foreign Body Removal
- Wound Debridement
- Assessment of Complications
Other Specialties
Orthopaedic Surgeon: āĻšāĻžā§, āĻā§ā§āύā§āĻ āĻŦāĻž āĻāĻā§āϰ musculoskeletal injury āĻĨāĻžāĻāϞā§āĨ¤
Hand Surgeon / Plastic Surgeon: āĻšāĻžāϤā§āϰ āĻāĻā§āϰ āĻā§āώāϤ, tendon injury, nerve injury āĻ āĻĨāĻŦāĻž āĻāĻāĻŋāϞ soft-tissue damage āĻĨāĻžāĻāϞā§āĨ¤
Suggested Referral Note
Referred to General Surgery for evaluation of penetrating soft-tissue injury with a history of foreign-body impaction, to assess for any retained foreign body and determine the need for surgical exploration, removal and wound debridement.
āĻŦāĻžāĻāϞāĻž āĻ āϰā§āĻĨ: āύāϰāĻŽ āĻāĻŋāϏā§āϝā§āϤ⧠āĻĻā§āϰā§āĻāĻāύāĻžāĻāύāĻŋāϤ āĻāĻāĻžāϤ āĻ āĻŦāĻžāĻāϰā§āϰ āĻŦāϏā§āϤ⧠āĻāĻāĻā§ āϝāĻžāĻā§āĻžāϰ āĻāϤāĻŋāĻšāĻžāϏ āĻĨāĻžāĻāĻžā§ Foreign Body āĻ āĻŦāĻļāĻŋāώā§āĻ āĻāĻā§ āĻāĻŋ āύāĻž āĻāĻŦāĻ surgical management āĻĒā§āϰā§ā§āĻāύ āĻāĻŋ āύāĻž, āϤāĻž āĻŽā§āϞā§āϝāĻžā§āύā§āϰ āĻāύā§āϝ āĻā§āύāĻžāϰā§āϞ āϏāĻžāϰā§āĻāĻžāϰāĻŋ āĻŦāĻŋāĻāĻžāĻā§ āϰā§āĻĢāĻžāϰ āĻāϰāĻž āĻšāϞā§āĨ¤
15. Final Clinical Diagnosis â Prescription-āĻ āĻā§ āϞāĻŋāĻāĻŦā§āύ?
Doctor’s Diagnosis
Dx: FB Impaction
āĻŦāĻžāĻāϞāĻž: āĻļāϰā§āϰā§āϰ āĻāĻŋāϏā§āϝā§āϰ āĻŽāϧā§āϝ⧠āĻŦāĻžāĻāϰā§āϰ āĻŦāϏā§āϤ⧠āĻāĻāĻā§ āϝāĻžāĻā§āĻžāĨ¤
My Clinical Working Diagnosis
Dx: Traumatic Penetrating Soft-Tissue Injury with Foreign Body Impaction (Rust-Contaminated Material).
āĻŦāĻžāĻāϞāĻž āĻ āϰā§āĻĨ
āĻĻā§āϰā§āĻāĻāύāĻžāĻāύāĻŋāϤ āĻāĻāĻžāϤ⧠āĻŽāϰāĻŋāĻāĻžāϝā§āĻā§āϤ āĻŦāĻžāĻāϰā§āϰ āĻŦāϏā§āϤ⧠āĻļāϰā§āϰā§āϰ āύāϰāĻŽ āĻāĻŋāϏā§āϝā§āϤ⧠āĻĒā§āϰāĻŦā§āĻļ āĻāϰ⧠āĻāĻāĻā§ āϝāĻžāĻā§āĻžāĨ¤
Short Clinical Diagnosis
Dx: Penetrating Soft-Tissue Injury with FB Impaction.
āĻāĻāĻŋ āĻŽā§āϞ āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύā§āϰ āϤāĻĨā§āϝā§āϰ āϏāĻā§āĻā§ āϏāĻžāĻŽāĻā§āĻāϏā§āϝāĻĒā§āϰā§āĻŖāĨ¤
Important Diagnostic Clarification
āϝāĻĻāĻŋ āĻŦāϰā§āϤāĻŽāĻžāύ āĻĒāϰā§āĻā§āώāĻžā§ Foreign Body āĻ āĻŦāĻļāĻŋāώā§āĻ āĻĨāĻžāĻāĻžāϰ āĻĒā§āϰāĻŽāĻžāĻŖ āύāĻž āĻĒāĻžāĻā§āĻž āϝāĻžā§, āϤāĻžāĻšāϞ⧠āĻāĻāύāĻāĻžāϰ Diagnosis āĻšāĻŋāϏā§āĻŦā§ Retained Foreign Body āϞā§āĻāĻž āϝāĻžāĻŦā§ āύāĻžāĨ¤
āϝāĻĻāĻŋ removal āĻāϤāĻŋāĻŽāϧā§āϝ⧠āϏāĻŽā§āĻĒāύā§āύ āĻšā§ā§ āĻĨāĻžāĻā§, āϤāĻžāĻšāϞ⧠āύāĻĨāĻŋāĻā§āĻā§āϤ āϤāĻĨā§āϝ āĻ āύā§āϝāĻžā§ā§ History of Foreign Body Impaction, S/P Foreign Body Removal āϞā§āĻāĻž āϝā§āϤ⧠āĻĒāĻžāϰā§āĨ¤
āϝāĻĻāĻŋ imaging āĻŦāĻž examination-āĻ Foreign Body āĻ āĻŦāĻļāĻŋāώā§āĻ āĻĨāĻžāĻāĻžāϰ āĻĒā§āϰāĻŽāĻžāĻŖ āĻĒāĻžāĻā§āĻž āϝāĻžā§, āϤāĻŦā§āĻ Retained Foreign Body āύāĻŋāĻļā§āĻāĻŋāϤāĻāĻžāĻŦā§ āϞā§āĻāĻž āϝāĻžāĻŦā§āĨ¤
16. Overview / Final Summary
| Clinical Parameter | Final Assessment |
|---|---|
| Chief Complaint | Accidental Impaction of Rusty Materials |
| Doctor’s Diagnosis | Foreign Body Impaction |
| My Working Diagnosis | Penetrating Soft-Tissue Injury with Foreign Body Impaction |
| Injury Type | Traumatic Penetrating Injury |
| Tetanus Risk | Wound characteristics and vaccination history need assessment |
| Antibiotic | Polycef 500 mg |
| Pain Medicine | Solivo 500 mg + 20 mg |
| Vaccine | Vaxitet |
| Passive Immunization | IG mentioned; preparation unconfirmed |
| Wound Antiseptic | Viodin Solution |
| Procedural Advice | Excision, Drainage, FB Removal and Debridement |
| Investigation | None explicitly prescribed |
| Primary Referral | General Surgeon |
Final Clinical Opinion
āĻāĻŋāĻāĻŋā§āϏāĻā§āϰ Diagnosis āĻāĻŦāĻ āĻāĻŽāĻžāϰ Clinical Working Assessment-āĻāϰ āĻŽāϧā§āϝ⧠āĻŽā§āϞāĻŋāĻ āĻā§āύ⧠āĻŦāĻŋāϰā§āϧ āύā§āĻāĨ¤
āĻāĻ āĻĒā§āϰā§āϏāĻā§āϰāĻŋāĻĒāĻļāύā§āϰ āĻĒā§āϰāϧāĻžāύ āϏāĻŽāϏā§āϝāĻž āĻšāϞ⧠Foreign Body Impaction following accidental penetrating injuryāĨ¤
āĻāĻŋāĻāĻŋā§āϏāĻā§āϰ prescribed management-āĻāϰ āĻŽā§āϞ āĻāĻĻā§āĻĻā§āĻļā§āϝ āĻāĻŋāϞ Foreign Body āĻ āĻĒāϏāĻžāϰāĻŖ, wound management, tetanus prevention āĻāĻŦāĻ āϏāĻŽā§āĻāĻžāĻŦā§āϝ bacterial complications āύāĻŋā§āύā§āϤā§āϰāĻŖāĨ¤
āϤāĻŦā§ āĻā§āώāϤā§āϰ āĻŦāϰā§āϤāĻŽāĻžāύ āĻ āĻŦāϏā§āĻĨāĻž āĻ āĻāĻŋāĻāĻŋā§āϏāĻž āϏāĻŽā§āĻĒāύā§āύ āĻšāĻā§āĻžāϰ āϤāĻĨā§āϝ āĻāĻžā§āĻž ongoing infection āĻŦāĻž retained foreign body āύāĻŋāĻļā§āĻāĻŋāϤ āĻāϰāĻž āϏāĻŽā§āĻāĻŦ āύā§āĨ¤
17. Reference List
A. Standard Medical Textbooks
1. Bailey & Love’s Short Practice of Surgery. 27th Edition. CRC Press; 2018. Relevant topics: Wound Management, Surgical Infection and Surgical Trauma.
2. Harrison’s Principles of Internal Medicine. 22nd Edition. McGraw Hill; 2025. Relevant topic: Tetanus.
3. Robbins & Cotran Pathologic Basis of Disease. 10th Edition. Elsevier; 2020. Relevant topics: Inflammation, Tissue Injury and Wound Healing.
4. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. Relevant sections: NSAIDs, Beta-lactam Antibiotics and Antiseptics.
B. Clinical Guidelines
5. CDC. Clinical Guidance for Wound Management to Prevent Tetanus. Updated 8 September 2026.
CDC Tetanus Wound Management Guidelines
6. WSES/AcEMC. Management of Traumatic Wounds in the Emergency Department. 2016.
WSES Traumatic Wound Management
C. Peer-Reviewed Journals with DOI
7. Prevaldi C, Paolillo C, Locatelli C, et al. Management of traumatic wounds in the Emergency Department: position paper from AcEMC and WSES. World Journal of Emergency Surgery. 2016;11:30.
DOI: 10.1186/s13017-016-0084-3
8. Rupert J, Honeycutt JD, Odom MR. Foreign Bodies in the Skin: Evaluation and Management. American Family Physician. 2020;101(12):740â747.
AAFP Foreign Body Evaluation and Management
D. MedEx Bangladesh â Verified Brand References
| Drug | MedEx Reference |
|---|---|
| Vaxitet | Vaxitet 40 IU/0.5 ml |
| Human Tetanus Immunoglobulin | Protet-IG 250 IU/ml |
| Polycef | Polycef 500 mg |
| Solivo | Solivo 500 mg + 20 mg |
| Viodin | Viodin 10% Solution |
FINAL PRESCRIPTION Dx:
Traumatic Penetrating Soft-Tissue Injury with Foreign Body Impaction (Rust-Contaminated Material).
āĻŦāĻžāĻāϞāĻž: āĻĻā§āϰā§āĻāĻāύāĻžāĻāύāĻŋāϤ āĻāĻāĻžāϤ⧠āĻŽāϰāĻŋāĻāĻžāϝā§āĻā§āϤ āĻŦāĻžāĻāϰā§āϰ āĻŦāϏā§āϤ⧠āύāϰāĻŽ āĻāĻŋāϏā§āϝā§āϤ⧠āĻĒā§āϰāĻŦā§āĻļ āĻāϰ⧠āĻāĻāĻā§ āϝāĻžāĻā§āĻžāĨ¤